CA2185653C
(en)
*
|
1994-03-16 |
2009-01-13 |
Kathleen M. Miller |
Stabilization of peptides and proteins for radiopharmaceutical use
|
EP0810853B1
(en)
*
|
1995-02-24 |
2004-08-25 |
Elan Pharma International Limited |
Aerosols containing nanoparticle dispersions
|
ES2112765B1
(en)
*
|
1995-08-02 |
1999-03-01 |
Cantabria Ind Farmaceutica Sa |
PROCEDURE FOR OBTAINING RADIOLOGICAL CONTRAST FORMULATIONS, FOR GASTROINTESTINAL EXPLORATIONS FOR EXTEMPORARY AND DIRECT USE.
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
US5879715A
(en)
*
|
1997-09-02 |
1999-03-09 |
Ceramem Corporation |
Process and system for production of inorganic nanoparticles
|
UA72189C2
(en)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
NZ511442A
(en)
*
|
1998-11-02 |
2003-02-28 |
Elan Corp Plc |
Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US20040141925A1
(en)
*
|
1998-11-12 |
2004-07-22 |
Elan Pharma International Ltd. |
Novel triamcinolone compositions
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
US6969529B2
(en)
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US9616150B2
(en)
*
|
1999-10-29 |
2017-04-11 |
Children's Hospital Los Angeles |
Bone hemostasis method and materials
|
KR20010045671A
(en)
*
|
1999-11-05 |
2001-06-05 |
강경석 |
Radiopaque Markers for Radiorogy Examinations
|
AU2001234005B2
(en)
*
|
2000-02-28 |
2006-01-19 |
Pharmakodex Limited |
Improvements in or relating to the delivery of oral drugs
|
US7276249B2
(en)
*
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US20030224058A1
(en)
*
|
2002-05-24 |
2003-12-04 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US7998507B2
(en)
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
US7198795B2
(en)
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US20080241070A1
(en)
*
|
2000-09-21 |
2008-10-02 |
Elan Pharma International Ltd. |
Fenofibrate dosage forms
|
US6623761B2
(en)
|
2000-12-22 |
2003-09-23 |
Hassan Emadeldin M. |
Method of making nanoparticles of substantially water insoluble materials
|
US6976647B2
(en)
*
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
WO2003000228A2
(en)
*
|
2001-06-22 |
2003-01-03 |
Elan Pharma International Ltd. |
Method for high through put screening using a small scale mill or microfluidics
|
US7758890B2
(en)
*
|
2001-06-23 |
2010-07-20 |
Lyotropic Therapeutics, Inc. |
Treatment using dantrolene
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
PT1429731E
(en)
*
|
2001-09-19 |
2007-04-30 |
Elan Pharma Int Ltd |
Nanoparticulate insulin formulations
|
DE60222160T2
(en)
|
2001-10-12 |
2008-06-12 |
Elan Pharma International Ltd., Athlone |
COMPOSITIONS COMPRISING PROPERTIES OF IMMEDIATE RELEASE AND CONTROLLED RELEASE
|
WO2003039601A1
(en)
*
|
2001-11-07 |
2003-05-15 |
Imcor Pharmaceutical Company |
Methods for vascular imaging using nanoparticulate contrast agents
|
US20030129242A1
(en)
*
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
AU2003210517A1
(en)
*
|
2002-02-04 |
2003-09-02 |
Elan Pharma International, Ltd. |
Drug nanoparticles with lysozyme surface stabiliser
|
US20040101566A1
(en)
*
|
2002-02-04 |
2004-05-27 |
Elan Pharma International Limited |
Novel benzoyl peroxide compositions
|
AU2003222027A1
(en)
*
|
2002-03-20 |
2003-10-08 |
Elan Pharma International Limited |
Fast dissolving dosage forms having reduced friability
|
EP1490030B2
(en)
*
|
2002-03-20 |
2010-07-14 |
Elan Pharma International Limited |
Nanoparticulate compositions of angiogenesis inhibitors
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
US20040076586A1
(en)
*
|
2002-03-28 |
2004-04-22 |
Reinhard Koening |
Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
|
US7101576B2
(en)
*
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
ES2380318T3
(en)
|
2002-04-12 |
2012-05-10 |
Alkermes Pharma Ireland Limited |
Megestrol nanoparticular formulations
|
US20100226989A1
(en)
*
|
2002-04-12 |
2010-09-09 |
Elan Pharma International, Limited |
Nanoparticulate megestrol formulations
|
US9101540B2
(en)
*
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
EP1503737B1
(en)
*
|
2002-05-06 |
2009-01-07 |
Elan Pharma International Limited |
Nanoparticulate nystatin formulations
|
US20070264348A1
(en)
*
|
2002-05-24 |
2007-11-15 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
WO2003103632A1
(en)
*
|
2002-06-10 |
2003-12-18 |
Elan Pharma International, Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
JP4776229B2
(en)
*
|
2002-07-16 |
2011-09-21 |
エラン ファーマ インターナショナル,リミティド |
Stable nanoparticulate active substance liquid dosage composition
|
DK1553927T3
(en)
*
|
2002-09-11 |
2011-01-31 |
Elan Pharma Int Ltd |
Gel-stabilized, nanoparticle active ingredient compositions
|
CA2500908A1
(en)
*
|
2002-10-04 |
2004-04-22 |
Elan Pharma International Limited |
Gamma irradiation of solid nanoparticulate active agents
|
ES2365012T3
(en)
*
|
2002-11-12 |
2011-09-20 |
Elan Pharma International Limited |
SOLID PHARMACEUTICAL FORMS OF QUICK DISINTEGRATION THAT ARE NOT RELIABLE AND UNDERSTANDING PULULANO.
|
WO2004058216A2
(en)
*
|
2002-12-17 |
2004-07-15 |
Elan Pharma International Ltd. |
Milling microgram quantities of nanoparticulate candidate compounds
|
JP4469846B2
(en)
*
|
2003-01-31 |
2010-06-02 |
エラン ファーマ インターナショナル,リミティド |
Nanoparticulate topiramate formulation
|
US20040208833A1
(en)
*
|
2003-02-04 |
2004-10-21 |
Elan Pharma International Ltd. |
Novel fluticasone formulations
|
US20050220870A1
(en)
*
|
2003-02-20 |
2005-10-06 |
Bonnie Hepburn |
Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
|
JP2006518751A
(en)
*
|
2003-02-20 |
2006-08-17 |
サンタラス インコーポレイティッド |
Novel formulation for rapid and sustained suppression of gastric acid, omeprazole antacid complex-immediate release
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
US8512727B2
(en)
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
WO2004098649A2
(en)
*
|
2003-05-06 |
2004-11-18 |
Philips Intellectual Property & Standards Gmbh |
Apparatus and method for examining an object by means of elastically scattered x-ray radiation and contrast agent
|
EP1626742A1
(en)
*
|
2003-05-22 |
2006-02-22 |
Elan Pharma International Limited |
Sterilization of dispersions of nanoparticulate active agents with gamma radiation
|
US8993599B2
(en)
|
2003-07-18 |
2015-03-31 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
ATE415946T1
(en)
*
|
2003-08-08 |
2008-12-15 |
Elan Pharma Int Ltd |
NEW METAXALONE COMPOSITIONS
|
US20050220881A1
(en)
*
|
2003-10-10 |
2005-10-06 |
Bvm Holding Co. |
Pharmaceutical composition
|
KR20060127857A
(en)
*
|
2003-10-29 |
2006-12-13 |
알투스 파마슈티컬스 인코포레이티드 |
Non-pancreatic proteases for controlling plasma cholecystokinin(cck) concentration and for treating pain
|
ES2366646T3
(en)
*
|
2003-11-05 |
2011-10-24 |
Elan Pharma International Limited |
COMPOSITIONS IN THE FORM OF NANOPARTICLES THAT HAVE A PEPTIDE AS A SURFACE STABILIZER.
|
AU2005213472A1
(en)
*
|
2004-02-10 |
2005-08-25 |
Santarus, Inc. |
Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
|
CA2561700A1
(en)
*
|
2004-04-16 |
2005-12-15 |
Santarus, Inc. |
Combination of proton pump inhibitor, buffering agent, and prokinetic agent
|
US8815916B2
(en)
|
2004-05-25 |
2014-08-26 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
US8906940B2
(en)
|
2004-05-25 |
2014-12-09 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
GB0414825D0
(en)
|
2004-07-02 |
2004-08-04 |
Biostatus Ltd |
Gel formulations and uses thereof
|
JP5324098B2
(en)
*
|
2004-11-16 |
2013-10-23 |
アルケルメス ファーマ アイルランド リミテッド |
Injectable nanoparticulate olanzapine formulation
|
US9149433B2
(en)
*
|
2004-11-30 |
2015-10-06 |
Basf Corporation |
Method for formation of micro-prilled polymers
|
UA89513C2
(en)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Nanoparticulate raloxifene hydrochloride composition
|
MX2007007342A
(en)
*
|
2004-12-15 |
2007-12-11 |
Elan Pharma Int Ltd |
Nanoparticulate tacrolimus formulations.
|
WO2006069098A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Elan Pharma International Ltd. |
Nanoparticulate bicalutamide formulations
|
MX2007008212A
(en)
*
|
2005-01-06 |
2007-08-16 |
Elan Pharma Int Ltd |
Nanoparticulate candesartan formulations.
|
EP1853234A2
(en)
*
|
2005-02-15 |
2007-11-14 |
Elan Pharma International Limited |
Aerosol and injectable formulations of nanoparticulate benzodiazepine
|
WO2006096462A1
(en)
*
|
2005-03-03 |
2006-09-14 |
Elan Pharma International Limited |
Nanoparticulate compositions of heterocyclic amide derivatives
|
WO2006099121A2
(en)
*
|
2005-03-10 |
2006-09-21 |
Elan Pharma International Limited |
Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
|
BRPI0606283A2
(en)
*
|
2005-03-16 |
2009-06-09 |
Elan Pharma Int Ltd |
nanoparticulate leukotriene receptor antagonist / corticosteroid formulations
|
CN101198316A
(en)
*
|
2005-03-17 |
2008-06-11 |
伊兰制药国际有限公司 |
Nanoparticulate bisphosphonate compositions
|
MX2007011772A
(en)
*
|
2005-03-23 |
2007-12-05 |
Elan Pharma Int Ltd |
Nanoparticulate corticosteroid and antihistamine formulations.
|
US20060246141A1
(en)
*
|
2005-04-12 |
2006-11-02 |
Elan Pharma International, Limited |
Nanoparticulate lipase inhibitor formulations
|
JP2008535921A
(en)
|
2005-04-12 |
2008-09-04 |
エラン・ファルマ・インターナショナル・リミテッド |
Nanoparticles containing cyclosporine and controlled release compositions
|
BRPI0607537A2
(en)
*
|
2005-04-12 |
2009-09-15 |
Elan Pharma Int Ltd |
nanoparticulate quinazoline derivative formulations
|
WO2006132752A1
(en)
*
|
2005-05-10 |
2006-12-14 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising vitamin k2
|
CA2607494A1
(en)
*
|
2005-05-10 |
2007-08-02 |
Elan Pharma International Limited |
Nanoparticulate clopidogrel formulations
|
US20100028439A1
(en)
*
|
2005-05-23 |
2010-02-04 |
Elan Pharma International Limited |
Nanoparticulate stabilized anti-hypertensive compositions
|
AU2006309295B2
(en)
*
|
2005-06-03 |
2012-04-26 |
Elan Pharma International Limited |
Nanoparticulate acetaminophen formulations
|
CA2610448A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Elan Pharma International, Limited |
Nanoparticulate imatinib mesylate formulations
|
WO2006133045A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Elan Pharma International, Limited |
Nanoparticulate benidipine compositions
|
WO2008073068A1
(en)
|
2005-06-08 |
2008-06-19 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising cefditoren
|
EP1898882B1
(en)
*
|
2005-06-09 |
2009-10-28 |
Elan Pharma International Limited |
Nanoparticulate ebastine formulations
|
AU2006259606A1
(en)
*
|
2005-06-13 |
2006-12-28 |
Elan Pharma International, Limited |
Nanoparticulate clopidogrel and aspirin combination formulations
|
US20100221327A1
(en)
*
|
2005-06-15 |
2010-09-02 |
Elan Pharma International Limited |
Nanoparticulate azelnidipine formulations
|
US20070015719A1
(en)
*
|
2005-07-07 |
2007-01-18 |
Elan Pharma International Limited |
Nanoparticulate clarithromycin formulations
|
JP2009507925A
(en)
*
|
2005-09-13 |
2009-02-26 |
エラン ファーマ インターナショナル リミテッド |
Nanoparticle tadalafil formulation
|
US20070148100A1
(en)
*
|
2005-09-15 |
2007-06-28 |
Elan Pharma International, Limited |
Nanoparticulate aripiprazole formulations
|
ES2812250T3
(en)
*
|
2005-11-28 |
2021-03-16 |
Marinus Pharmaceuticals Inc |
Ganaxolone formulations and procedures for their preparation and use
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
NZ573555A
(en)
*
|
2006-05-30 |
2012-09-28 |
Elan Pharma Int Ltd |
Nanoparticulate posaconazole formulations
|
JP2009543797A
(en)
*
|
2006-07-10 |
2009-12-10 |
エラン ファーマ インターナショナル,リミティド |
Nanoparticulate sorafenib formulation
|
BRPI0714173A2
(en)
*
|
2006-07-12 |
2012-12-25 |
Elan Pharma Int Ltd |
stable nanoparticulate composition, methods for preparing the composition, for preventing and / or treating disease conditions, symptoms, syndromes and conditions of the central nervous system, for improving or maintaining bioavailability of modafinil, and for treating neurologically based disorder, pharmaceutical composition, and dosage form
|
BRPI0717721A2
(en)
|
2006-11-28 |
2013-10-29 |
Marinus Pharmaceuticals |
"COMPLEX DRUG PARTICLES, PHARMACEUTICAL COMPOSITION, USE OF A PHARMACEUTICAL COMPOSITION, COMPLEX DRUG PARTICLES STABILIZED IN THE SIZE, METHOD FOR THE PREPARATION OF STABILIZED DRUG PARTICLES, EMOTIONAL COMPOSITION IN PHARMACEUTICAL, PHARMACEUTICAL UNDERSTANDING
|
GB0625322D0
(en)
*
|
2006-12-19 |
2007-01-24 |
Pharmakodex Ltd |
Pharmaceutical compositions
|
WO2009117401A2
(en)
*
|
2008-03-21 |
2009-09-24 |
Elan Pharama International Limited |
Compositions for site-specific delivery of imatinib and methods of use
|
WO2010009075A1
(en)
*
|
2008-07-14 |
2010-01-21 |
The University Of North Carolina At Chapel Hill |
Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds
|
US20100081956A1
(en)
*
|
2008-09-30 |
2010-04-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Method, composition, and system to control pH in pulmonary tissue of a subject
|
DK3045043T3
(en)
|
2009-02-26 |
2020-08-03 |
Relmada Therapeutics Inc |
ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINANE WITH EXTENDED RELEASE AND METHOD OF USE
|
WO2010138539A2
(en)
|
2009-05-27 |
2010-12-02 |
Elan Pharma International Ltd. |
Reduction of flake-like aggregation in nanoparticulate active agent compositions
|
FR2945950A1
(en)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
ANTICANCER NANOPARTICLE COMPOSITIONS AND METHODS FOR PREPARING THE SAME
|
US8889193B2
(en)
|
2010-02-25 |
2014-11-18 |
The Johns Hopkins University |
Sustained delivery of therapeutic agents to an eye compartment
|
WO2011146583A2
(en)
|
2010-05-19 |
2011-11-24 |
Elan Pharma International Limited |
Nanoparticulate cinacalcet formulations
|
US10307372B2
(en)
|
2010-09-10 |
2019-06-04 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
CA2867203C
(en)
|
2012-03-16 |
2016-09-20 |
The Johns Hopkins University |
Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
|
WO2013138343A1
(en)
|
2012-03-16 |
2013-09-19 |
The Johns Hopkins University |
Controlled release formulations for the delivery of hif-1 inhibitors
|
US9827191B2
(en)
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
JP6360040B2
(en)
|
2012-05-03 |
2018-07-18 |
カラ ファーマシューティカルズ インコーポレイテッド |
Mucus-permeable coated particles, compositions, pharmaceutical compositions, pharmaceutical formulations, and methods for forming them
|
WO2013166385A1
(en)
|
2012-05-03 |
2013-11-07 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
CA2872519C
(en)
|
2012-05-04 |
2017-09-05 |
The Johns Hopkins University |
Lipid-based drug carriers for rapid penetration through mucus linings
|
WO2014124006A1
(en)
|
2013-02-05 |
2014-08-14 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
CN107635545A
(en)
|
2015-01-27 |
2018-01-26 |
约翰霍普金斯大学 |
For strengthening the hypotonic aqueogel of the conveying of activating agent at mucomembranous surface
|
EP3288957A4
(en)
|
2015-05-01 |
2019-01-23 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
CN109715151A
(en)
|
2016-08-11 |
2019-05-03 |
奥维德医疗公司 |
For treating the method and composition of epilepsy sexual disorder
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
EP4009982A4
(en)
|
2019-08-05 |
2023-08-09 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treatment of status epilepticus
|
AU2020395254A1
(en)
|
2019-12-06 |
2022-06-02 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating tuberous sclerosis complex
|